LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

524.28 -0.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

517.92

Max

525

Pagrindiniai rodikliai
By Trading Economics
Pajamos	26M 364M
Pardavimai	-9.3M 790M
P/E Sektoriaus vid.	19.192 57.833
Pelno marža	46.102
Darbuotojai	1,400
EBITDA	61M 524M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+4.14% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2B 23B
Ankstesnė atidarymo kaina	524.31
Ankstesnė uždarymo kaina	524.28

Naujienos nuotaikos

By Acuity

50%

147 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-22 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-22 23:50; UTC

Rinkos pokalbiai

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-22 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

2026-03-22 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

2026-03-22 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Participated in Aurum Resources Equity Raising

2026-03-22 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

2026-03-22 22:22; UTC

Rinkos pokalbiai

Svarbiausios naujienos

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

2026-03-22 21:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

2026-03-22 21:22; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

2026-03-22 21:21; UTC

Rinkos pokalbiai

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

4.14% į viršų

12 mėnesių prognozė

Vidutinis 546 USD 4.14%

Aukščiausias 705 USD

Žemiausias 35 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

147 / 350 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.